To determine the effect of oral administration of a protease inhibitor on the evolution of reflux esophagitis after gastric surgery studies were performed in both rats and clinical cases. 1) Experimental study: Four experimental operative procedures were performed in Sprague-Dawley rats to investigate effects on esophageal reflux content. Two weeks after surgery, the area of esophageal ulcer in TG (total gastrectomy with Billroth II reconstruction), TG+PBD (total gastrectomy and biliary and pancreatic juice diversion), TG+PR (total gastrectomy and biliary diversion) and TG+BR (total gastrectomy and pancreatic juice diversion) was 161.7 ± 25.5 mm2, 0 ± 0 mm2, 19.0 ± 7.1 mm2 and 0 ± 0 mm2, respectively. The area of esophageal ulcer one or two weeks after oral administration of CAMOSTAT was determined. There were significant differences between non-treated TG group and two week-treated group. 2) Clinical study: The subjective symptoms improved in 63% and 71.4% of patients at two and four weeks after administration of CAMOSTAT. Endoscopic findings also improved in 84% of cases four weeks after treatment. These results suggest that pancreatic juice is a major factor in the pathogenesis of reflux esophagitis after surgery, and oral administration of CAMOSTAT is an effective therapy.
|Number of pages||7|
|Issue number||SUPPL. 1|
|Publication status||Published - 1989|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)